刺激性肠综合征的护士管理的肠导向催眠疗法:为期两年的随访研究
Jenny Lövdahl1, Michaela Blomqvist-Storm1,2, Olafur S Palsson3
1Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
United European gastroenterology journal
|June 10, 2025
概括
由护士管理的肠道导向催眠疗法可以为刺激性肠综合征 (IBS) 症状提供持久的缓解. 这种有效的治疗方法在两年内持续改善症状,使IBS患者受益.
科学领域:
- 胃肠病学 胃肠病学
- 精神病体医学是一种精神病体医学.
- 临床心理学 临床心理学
背景情况:
- 肠导向性催眠疗法是对刺激性肠综合征 (IBS) 的一项成熟治疗方法.
- 以前的研究表明,长期治疗效果的可能性很大.
- 护士对IBS进行的催眠治疗的长期结果仍然被低估.
研究的目的:
- 调查护士对IBS进行的肠道导向催眠疗法的长期疗效.
- 确定与接受催眠治疗的IBS患者症状改善相关的因素.
- 为了比较个人与集体催眠疗法对IBS的治疗效果.
主要方法:
- 一项为期2年的随访研究,涉及289名IBS患者,他们完成了为期12周的催眠疗法计划 (个人或团体).
- 刺激性肠综合征和症状严重程度 (IBS-SSS),胃肠特异性焦虑 (VSI) 和焦虑和抑郁症状 (HADS) 在基线和6个月,1年和2年的随访评估.
- 治疗响应者被定义为那些在IBS-SSS中减少≥50点的人.
主要成果:
- 在整个2年的随访期间,观察到持续响应率约为61.8%至64.7%.
- 在两年内,IBS症状,结肠外症状和心理困扰的显著减少得到维持 (p < 0.001).
- 年龄较小,个人催眠疗法和严重的基线IBS症状预测了更好的治疗反应 (R2 = 0.16).
结论:
- 护士管理的肠道导向催眠疗法为IBS患者提供了有效和长期的症状缓解.
- 诸如年轻年龄,严重的IBS症状和个体治疗形式等因素可能会提高治疗的有效性.
- 这项研究支持了催眠疗法作为IBS治疗方式的长期效用.
相关概念视频
Irritable Bowel Syndrome III: Medical and Nursing Management
646
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
646
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
736
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
736
Assessment of the Gastrointestinal System I: Subjective Data
627
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
627
Drugs for Treatment of Diarrhea-Predominant IBS
636
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
636
Drugs for Treatment of Constipation-Predominant IBS
732
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
732
Irritable Bowel Syndrome I: Introduction
929
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
929

